<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="83460"><DrugName>Alfalastin</DrugName><DrugNamesKey><Name id="43002406">Alfalastin</Name></DrugNamesKey><DrugSynonyms><Name><Value>Alfalastin</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="25256">LFB SA</CompanyOriginator><CompaniesPrimary><Company id="25256">LFB SA</Company></CompaniesPrimary><CrossReferences><SourceEntity id="25256" type="Company"><TargetEntity id="5001330788" type="organizationId">LFB Biotechnologies SAS</TargetEntity></SourceEntity><SourceEntity id="1298" type="ciIndication"><TargetEntity id="E88.01" type="ICD10"/><TargetEntity id="273.4" type="ICD9"/><TargetEntity id="10001806" type="MEDDRA"/><TargetEntity id="D019896" type="MeSH"/><TargetEntity id="60" type="ORPHANET"/><TargetEntity id="-582324492" type="omicsDisease"/><TargetEntity id="2511" type="siCondition"/></SourceEntity><SourceEntity id="PTGT-00105" type="ciTarget"><TargetEntity id="33957486452653" type="siTarget">Alpha-1-antitrypsin</TargetEntity><TargetEntity id="-955295907" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Alpha-1 antitrypsin deficiency - France - Jan-2006</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication></IndicationsPrimary><ActionsPrimary><Action id="732">Alpha 1 antitrypsin stimulator</Action></ActionsPrimary><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-06-29T06:15:57.000Z</LastModificationDate><ChangeDateLast>2019-07-01T00:00:00.000Z</ChangeDateLast><AddedDate>2013-02-21T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="25256" linkType="Company"&gt;LFB Biotechnologies&lt;/ulink&gt; has developed and launched Alfalastin, injectable human alpha-1 antitrypsin (AAT), for the iv treatment of primary AAT deficiency in patients with pulmonary emphysema. The drug was presumed to have been launched shortly afterwards [&lt;ulink linkID="1385321" linkType="Reference"&gt;1385321&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In January 2006, the HAS recommended approval of Alfalastin for the treatment of primary AAT deficiency in subjects with the PiZZ or PiSZ phenotype with pulmonary emphysema. The drug was previously available under a temporary authorization for use since 1995 [&lt;ulink linkID="1385321" linkType="Reference"&gt;1385321&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2005, the drug was granted Orphan Drug status in Taiwan for the treatment of primary AAT deficiency in patients with pulmonary emphysema [&lt;ulink linkID="1685979" linkType="Reference"&gt;1685979&lt;/ulink&gt;], [&lt;ulink linkID="1941147" linkType="Reference"&gt;1941147&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="25256">LFB SA</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate>2006-01-04T00:00:00.000Z</StatusDate><Source id="1385307" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25256">LFB SA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate>2005-01-28T00:00:00.000Z</StatusDate><Source id="1685979" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="25256">LFB SA</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate>2006-01-04T00:00:00.000Z</StatusDate><Source id="1385307" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="25256">LFB SA</OwnerCompany><Country id="TW">Taiwan</Country><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><AwardedIndication>primary AAT deficiency in patients with pulmonary emphysema</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2005-01-28T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00105"><Name>Alpha 1 antitrypsin</Name><SwissprotNumbers><Swissprot>O00394</Swissprot><Swissprot>O54763</Swissprot><Swissprot>P01009</Swissprot><Swissprot>P01010</Swissprot><Swissprot>P07758</Swissprot><Swissprot>P12725</Swissprot><Swissprot>P17475</Swissprot><Swissprot>P22324</Swissprot><Swissprot>P22325</Swissprot><Swissprot>P22599</Swissprot><Swissprot>P22922</Swissprot><Swissprot>P23035</Swissprot><Swissprot>P26595</Swissprot><Swissprot>P32759</Swissprot><Swissprot>P34955</Swissprot><Swissprot>P38026</Swissprot><Swissprot>P38027</Swissprot><Swissprot>P38028</Swissprot><Swissprot>P38029</Swissprot><Swissprot>P38030</Swissprot><Swissprot>P38031</Swissprot><Swissprot>P50447</Swissprot><Swissprot>P97277</Swissprot><Swissprot>Q00896</Swissprot><Swissprot>Q00897</Swissprot><Swissprot>Q00898</Swissprot><Swissprot>Q03044</Swissprot><Swissprot>Q5RCW5</Swissprot><Swissprot>Q63969</Swissprot><Swissprot>Q64118</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></drugRecordOutput>